Kallen J, Welzenbach K, Ramage P, Geyl D, Kriwacki R, Legge G, Cottens S, Weitz-Schmidt G, Hommel U
Preclinical Research, NOVARTIS PHARMA AG, Basel, CH 4002, Switzerland.
J Mol Biol. 1999 Sep 10;292(1):1-9. doi: 10.1006/jmbi.1999.3047.
The lymphocyte function-associated antigen (LFA-1) belongs to the family of beta2-integrins and plays an important role in T-cell activation and leukocyte migration to sites of inflammation. We report here that lovastatin, a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor intercellular adhesion molecule-1. Using nuclear magnetic resonance spectroscopy and X-ray crystallography we show that the inhibitor binds to a highly conserved domain of the LFA-1 alpha-chain called the I-domain. The first three-dimensional structure of an integrin inhibitor bound to its receptor reveals atomic details for a hitherto unknown mode of LFA-1 inhibition. It also sheds light into possible mechanisms of LFA-1 mediated signalling and will support the design of novel anti-adhesive and immunosuppressive drugs.
淋巴细胞功能相关抗原(LFA-1)属于β2整合素家族,在T细胞活化以及白细胞迁移至炎症部位过程中发挥重要作用。我们在此报告,临床上用于降低胆固醇水平的药物洛伐他汀可抑制人LFA-1与其反受体细胞间黏附分子-1的相互作用。利用核磁共振光谱法和X射线晶体学,我们表明该抑制剂结合至LFA-1α链一个名为I结构域的高度保守区域。一种整合素抑制剂与其受体结合的首个三维结构揭示了LFA-1抑制作用一种迄今未知模式的原子细节。它还为LFA-1介导信号传导的可能机制提供了线索,并将有助于新型抗黏附及免疫抑制药物的设计。